Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.
In a recent landmark trial of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) isolates, vancomycin MICs were >or=1 microg/ml for only 16% of the isolates, and accessory gene regulator (agr) function as measured by delta-hemolysin activity was absent or reduced in only 28.1% of the isolates. This clinical study did not capture a population of MRSA isolates predictive of vancomycin treatment failure.
McCalla
Carlo
C
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA. george_sakoulas@nymc.edu
Smyth
Davida S
DS
Robinson
D Ashley
DA
Steenbergen
Judith
J
Luperchio
Steven A
SA
Moise
Pamela A
PA
Fowler
Vance G
VG
Sakoulas
George
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D017576:Daptomycin / Q000494:pharmacology / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology; D005838:Genotype; D006460:Hemolysin Proteins / Q000235:genetics / Q000378:metabolism; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000145:classification* / Q000187:drug effects / Q000235:genetics*; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D006460:Hemolysin Proteins; D014640:Vancomycin; C025994:delta hemolysin protein, Staphylococcus aureus; D017576:Daptomycin